Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes

M Diagnósticos S.L.0 个研究点目标入组 225 人开始时间: 2018年9月17日最近更新: 2023年9月26日

适应症

试验速览

暂无简介。

•Patients with a previous diagnosis of type 2 diabetes and
•- Estimated glomerular filtration rate (eGFR) > 30mL/min x1,73m2and
•- Diagnosis of essential hypertension established at least one year before inclusion visit and suboptimal BP control (office BP above 140/70 mmHg)
•- HbA1C 7.5-10%
•- Albuminuria levels = 30 mg/g of creatinine
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 140
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 85

•- Age < 18 years old or = 75 years old.
•- Women of childbearing potential
•- Type 1 diabetes
•- Albuminuria above 3000 mg/g of creatinine
•- Established cardiovascular disease (stable heart failure, peripheral arterial disease or myocardial infarction or stroke within the previous 6 months)
•- Intolerance to dapagliflozin
•- On treatment with loop diuretic
•- Patients who routinely work during nightime (period between 11.00 p.m. and 7.00 a.m.)

发起方

M Diagnósticos S.L.